A Post-marketing Observational Study for ABBV-951 in Patients Diagnosed With Advanced Parkinson's Disease (aPD)
Latest Information Update: 31 May 2025
At a glance
- Drugs Foscarbidopa/Foslevodopa
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors AbbVie
Most Recent Events
- 03 Mar 2025 Planned End Date changed from 5 Jul 2026 to 1 Jul 2026.
- 03 Mar 2025 Planned primary completion date changed from 5 Jul 2026 to 1 Jul 2026.
- 19 Dec 2023 Status changed from not yet recruiting to recruiting.